Clinical Trials
3 trialsNCT02977780 2025-11-10
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT02981940 2025-09-02
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04118036 2025-08-11
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn